We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

DIAZYME LABORATORIES

Diazyme develops diagnostic reagents using its proprietary enzyme technologies that can be used on most automated che... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Performance of Five Lipoprotein(a) Immunoassays Evaluated

By LabMedica International staff writers
Posted on 06 Apr 2021
Print article
Image: The Diazyme Lipoprotein A assay kit is for the in vitro quantitative determination of Lp(a) concentration in human serum or plasma on Clinical Chemistry Systems (Photo courtesy of Diazyme)
Image: The Diazyme Lipoprotein A assay kit is for the in vitro quantitative determination of Lp(a) concentration in human serum or plasma on Clinical Chemistry Systems (Photo courtesy of Diazyme)
Increased serum Lipoprotein(a) [Lp(a)] is considered an independent, inherited risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke. This risk is believed to be due to pro-atherogenic, pro-inflammatory, and pro-thrombotic properties of the Lp(a) particle.

Lp(a) can be measured using a variety of methods, including enzyme linked immunosorbent assays (ELISA), latex-agglutination, immunoturbidimetry/immunonephelometry, electrophoresis, and immunofixation electrophoresis (IFE). A confounding factor is that Lp(a) can be reported in either mass units (mg/dL of the total Lp(a) particle) or molar concentration of particles (nmol/L).

Medical Laboratorians at the ARUP Institute of Clinical and Experimental Pathology (Salt Lake City, UT, USA) and their colleagues used 80 residual serum samples, and specimens from 120 self-reported healthy subjects (61 females/59 males) were also tested in a study. The aim of the study was to evaluate performance characteristic of five different Lp(a) assays using the cobas c501 analyzer (Roche Diagnostics, Indianapolis, IN, USA).

The five assay for Lp(a) used were from: Diazyme (Poway, CA, USA), Kamiya Biomedical Company (Seattle, WA, USA), MedTest Dx (Canton, MI, USA), Randox Laboratories (Crumlin, UK) and Roche Diagnostics, configured to mg/dL units. Assays from Diazyme and Kamiya were also configured using nmol/L units in separate studies. Studies included sensitivity, imprecision, linearity, method comparison, and evaluation of healthy subjects. Imprecision (intra-day, 20 replicates; inter-day, duplicates twice daily for five days) and linearity were evaluated using patient pools. Linearity assessed a minimum of five patient splits spanning the analytical measurement range (AMR).

The scientists reported that all methods met manufacturer claims regarding sensitivity: observed (manufacturer claim): Diazyme, 0.7 mg/dL (1.3 mg/dL); Kamiya, 1.2 mg/dL (5.0 mg/dL); MedTest, 0.2 mg/dL (1.3 mg/dL); Randox, 0.7 mg/dL (3.0 mg/dL); Roche, 0.3 mg/dL (4.0 mg/dL). Lp(a) assays also demonstrated acceptable imprecision and met manufacturers’ claims, with CVs less than 6% in all cases. Imprecision studies demonstrated %CVs ranging from 2.5 – 5.2% for the low pool (average concentration from 7.3 – 12.4 mg/dL); high pool %CVs ranged from 0.8 – 3.0% (average concentrations from (31.5 – 50.2 mg/dL). Linearity was confirmed for all assays. Variation in accuracy was observed when comparing results to an all method average. Lp(s) results were higher in females versus males in self-reported healthy subjects.

The authors concluded that all assays performed according to manufacturer described performance characteristics, although differences were observed across Lp(a) assays tested when compared to an all method average. The study was published on March 24, 2021 in the journal Practical Laboratory Medicine.

Related Links:
ARUP Institute of Clinical and Experimental Pathology
Roche Diagnostics
Diazyme
Kamiya Biomedical Company
MedTest Dx
Randox Laboratories


Gold Supplier
POC Analyzer
Epithod 616
New
Gold Supplier
SARS-CoV-2 Antibody Test
SARS-CoV-2 UTAB FS
New
Molecular Diagnostics Integrated System
SENTiNAT 200
New
SARS-CoV-2 RUO Solution
QuantiFERON SARS-CoV-2 RUO

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.